Welcome to a new episode of the Benzinga Psychedelics Podcast where we're joined byRobert Barrow, CEO of Mind Medicine(MindMed) (NASDAQ:MNMD), which has taken the development of LSD-based therapy to new heights. The biopharma company recently obtained a "breakthrough therapy" designation for the treatment of generalized anxiety from the U.S. Food and Drug Administration (FDA.)
LSD, illegal in the U.S., is classified by the Drug Enforcement Agency (DEA) as a Schedule I drug -meaning it has a high potential for abuse and no currently accepted medical treatments.
However, there is growing interest in LSD...
Login or create a forever free account to read this news
Sign up/Log in